内皮素受体拮抗剂CPU0213 对博莱霉素及油酸的小鼠肺损伤及纤维化的改善作用

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (9): 998-1003.

内皮素受体拮抗剂CPU0213 对博莱霉素及油酸的小鼠肺损伤及纤维化的改善作用

李娜, 王秋娟, 戴德哉, 贺海波, 冯瑜, 戴茵

中国药科大学药理研究室, 南京210009, 江苏

收稿日期:2007-06-15 修回日期:2007-08-13 出版日期:2007-09-26 发布日期:2020-10-30
通讯作者: 戴德哉, 男, 教授, 研究方向:心血管药理。Tel:025-83271270 E-mail:dezaidai@vip.sina.com
作者简介:李娜, 女, 博士生, 研究方向:心血管药理。
基金资助:
国家自然科学基金面上课题(30670760)资助项目

Endothelin receptor antagonist CPU0213 improves pulmonary injury and fibrosis induced by bleomycin and oleic acid in mice

LI Na, WANG Qiu-juan, DAI De-zai, HE Hai-bo, FENG Yu, DAI Yin

Research Division of Pharmacology, China Pharmaceutical University, Nanjing 210009, Jiangsu, China

Received:2007-06-15 Revised:2007-08-13 Online:2007-09-26 Published:2020-10-30

摘要/Abstract

摘要： 目的:本实验采用两种小鼠急性肺损伤与肺纤维化相关的模型, 探讨新内皮素受体拮抗剂CPU0213 对肺纤维化病变明显的肺动脉高压是否具有改善作用。方法:实验分正常组、博莱霉素或油酸模型组、阳性药硝苯地平(10 mg/kg) 组和CPU0213(50、100、200 mg/kg) 治疗组(n=10)。博莱霉素模型中, 观察肺重系数、支气管肺泡灌洗液(BALF) 回收率、BALF 白细胞数量及分类、丙二醛(MDA) 含量以及肺组织羟脯氨酸含量。油酸模型中, 小鼠尾静脉注射伊文氏兰(50 mg/kg) 1 h 后, 接着静注油酸100 mg/kg, 4 h 后分离左肺, 烘干后测定小鼠左肺中伊文氏兰的含量。结果:CPU0213 50、100、200 mg/kg可以降低肺重系数, 减少肺组织和血清MDA 含量,减少肺组织羟脯氨酸含量, 降低油酸所致肺纤维化模型中肺组织通透性的增加。其中, CPU0213200 mg/kg 的治疗效果优于阳性药硝苯地平(10 mg/kg)。结论:内皮素受体拮抗剂CPU0213 能减轻小鼠两种急性肺损伤与纤维化病变, 对临床肺动脉高压有较好疗效。

关键词: 博莱霉素, 内皮素受体拮抗剂, 油酸, 肺纤维化, 肺动脉高压

Abstract: AIM: Pulmonary fibrosis (PF) is closely related to progression of pulmonary artery hypertension. The study is aimed to investigate the effects of endothelin receptor antagonist CPU0213 on PF induced by bleomycin or oleic acid in mice.METHODS: Mice were divided into control, PF model, nifedipine treated (p.o.10 mg·kg^-1 ·d^-1), and CPU0213 (p.o.50 mg ·kg^-1 · d^-1), CPU0213(p.o.100 mg·kg^-1·d^-1), CPU0213 (p.o.200 mg·kg^-1 ·d^-1) treated groups (n=10).In bleomycin-induced PF model, the lung weight index, recovery of bronchioalveolar lavage fluid (BALF), leukocytes in BALF and biochemical assay of malondialdehyde (MDA) and hydroxyproline were delected.In oleic acidinduced acute lung injury model, mice received intravenous injection of Evan's blue, and 4hr later the content of Evan's blue in lung were measured.RESULTS: CPU0213 and nifedipine were effective in decreasing lung weight, suppressing inflammatory reactions, oxidative stress, and the accumulation of hydroxyproline in bleomycin- induced PF model.In acute lung injury model, the content of Evan's blue in lung was reduced by CPU0213 and nifedipine.The improvement made by CPU0213 200 mg/kg was better than nifedipine 10 mg/kg.CONCLUSION: Endothelin receptor antagonist CPU0213 showed favorable ability to reverse changes developed in PF. CPU0213 may be promising in the treatment of pulmonary artery hypertension in clinical settings.

Key words: bleomycin, endothelin receptor antagonists, oleic acid, pulmonary fibrosis, pulmonary artery hypertension

中图分类号:

R965.2

李娜, 王秋娟, 戴德哉, 贺海波, 冯瑜, 戴茵. 内皮素受体拮抗剂CPU0213 对博莱霉素及油酸的小鼠肺损伤及纤维化的改善作用[J]. 中国临床药理学与治疗学, 2007, 12(9): 998-1003.

LI Na, WANG Qiu-juan, DAI De-zai, HE Hai-bo, FENG Yu, DAI Yin. Endothelin receptor antagonist CPU0213 improves pulmonary injury and fibrosis induced by bleomycin and oleic acid in mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(9): 998-1003.

参考文献

1 Uguccioni M, Pulsatelli L, Grigolo B, et al.Endothelin-1 in idiopathic pulmonary fibrosis [J].J Clin Pathol, 1995;48:330-334.
2 Abraham DJ, Vancheeswaran R, Dashwood MR, et al.Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease [J].Am J Pathol, 1997;151:831-841.
3 Hocher B, Schwarz A, Fagan KA, et al.Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice [J].Am J Respir CellMol Biol, 2000;23:19-26.
4 Chua F, Gauldie J, Laurent GJ.Pulmonary fibrosis:searching for model answers [J].Am J Respir Cell Mol Biol, 2005;33:9-13.
5 Park SH, Saleh D, Giaid A, et al.Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist [J].Am J Respir Crit Care Med, 1997;156 :600-608.
6 Zhou Z, Kozlowski J, Schuster DP.Physiologic, biochemical, and imaging characterization of acute lung injury in mice [J]. Am J Respir Crit Care Med, 2005;172 :344-351.
7 戴德哉, 吉民, 黄敏, 等.内皮素受体拮抗剂CPU 0213 的生物活性及抑制ETA 及ETB 受体的作用 [J].中国药科大学学报, 2004;35:552-557.
8 Cui B, Feng Y, Dai DZ, et al.CPU0213, a novel endothelin receptor antagonist, relieves hypoxic pulmonary hypertension in rats by suppressing excessive ET-ROS pathway [J].Drug Dev Res, 2007;68 :42-50.
9 崔冰, 戴德哉.肺动脉高压药物治疗研究进展 [J].药学进展, 2004;28:149-153.
10 胡萍, 高占成.博莱霉素致小鼠肺纤维化模型的动态演变及其发生机制 [J].中国危重病急救医学, 2006;18 : 474-478.
11 Klings ES, Farber HW.Current management of primary pulmonary hypertension [J].Drugs, 2001;61:1945-1956.
12 Cockrill BA, Kacmarek RM, Fifer MA, et al.Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension [J].Chest, 2001;119 :128-136.
13 李振华, 孙吉臻, 侯显明.弥漫性间质性肺疾病支气管-肺泡灌洗液细胞学检查的临床意义 [J].中华内科杂志, 1990;29:2-4.
14 Zhou Z, Kozlowski J, Schuster DP.Physiologic, Biochemical, and Imaging Characterization of Acute Lung Injury inMice [J]. Am J Respir Crit Care Med, 2005;172 :344-351.
15 钱皓瑜, 齐景宪, 高元勋.红霉素对小鼠气管和肺微血管通透性的影响 [J].中华结核和呼吸杂, 1999;22:509.
16 卫张蕊, 周国锋, 田琼.炎症细胞和细胞因子在肺纤维化中作用的研究进展 [J].细胞与分子免疫学杂志, 2005;21:S85-S87.
17 刘瑞, 李成刚, 粱欣, 等.博莱霉素诱导大鼠肺纤维化过程中羟脯氨酸及氧化应激指标的变化 [J].第四军医大学学报, 2004;25:2202-2205.
18 Teder P, Noble PW.A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis [J].Am J Respir Cell Mol Biol, 2000;23 :7-10.
19 Mutsaers SE, Foster ML, Chambers RC, et al.Increased endothelin-1 and its localization during the development of bleomycin induced pulmonary fibrosis in mrs [J].Am Respir CellMol Biol, l998;18:611-619.
20 Clozel M, Breu V, Gray GA, et al.Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist [J].J Pharmacol Exp Ther, 1994; 270:228-235.
21 陆月明.油酸致急性肺损伤动物模型析评 [J].中华急诊医学杂志, 2005;l4 :81-83.
22 Hubloue I, Biarent D, Abdel Kafi S, et al.Endothelin receptor blockade in canine oleic acid-induced lung injury [J].Intensive Care Med, 2003;29 :1003-1006.
23 Sturani C, Papiris S, Galavotti V, et al.Pulmonary vascular responsiveness at rest and during exercise in idiopathic pulmonary fibrosis :effects of oxygen and nifedipine [J].Respiration, 1986;50:117-129.
24 刘海林, 杨少平, 陆汉明, 等.维拉帕米、硝苯地平对人成纤维细胞增殖、胶原和透明质酸合成的抑制作用 [J].中国药理学通报, 1996;12:456-458.

[1]	刘理静, 钱红, 孟庆欣, 张翔, 贺彬, 贺兼斌, 魏英民. 青藤碱激活Keap1/Nrf2信号通路抑制氧化应激和肺纤维化[J]. 中国临床药理学与治疗学, 2023, 28(9): 979-987.
[2]	李雅亭, 岳红梅, 刘苗苗, 许金回, 武兴东, 朱浩斌. 磷酸二酯酶4抑制剂作为特发性肺纤维化药物治疗的可能性[J]. 中国临床药理学与治疗学, 2023, 28(7): 818-823.
[3]	刘南玉, 岳红梅, 宋佩佩, 魏继芳, 魏雅倩, 谢莹莹, 王嘉琪. PDE4抑制剂作为肺纤维化的治疗靶点[J]. 中国临床药理学与治疗学, 2023, 28(3): 355-360.
[4]	王洁, 李龙, 陈凤, 刘胜菲. 二甲双胍干预肺纤维化发病机制的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 235-240.
[5]	沈畅, 艾可龙, 胡长平. 低氧诱导因子1信号通路调控低氧性肺动脉高压研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 114-120.
[6]	刘南玉, 岳红梅, 宋佩佩, 魏继芳, 魏雅倩, 谢莹莹, 王嘉琪. 以αv为靶向的整合素作为肺纤维化的药物靶点[J]. 中国临床药理学与治疗学, 2022, 27(6): 709-714.
[7]	李雪恒, 李龙. 褪黑素与特发性肺纤维化关系的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(6): 715-720.
[8]	魏继芳, 岳红梅, 刘南玉, 宋佩佩, 谢莹莹, 王嘉琪, 魏雅倩. 甲状腺激素与特发性肺纤维化相关性的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(3): 307-313.
[9]	孟时, 王中群. 人类免疫缺陷病毒相关性肺动脉高压研究进展[J]. 中国临床药理学与治疗学, 2022, 27(12): 1431-1440.
[10]	周世琴, 骆亚莉, 周雯, 齐晓风, 肖孟勇. 肺纤维化的相关分子机制和治疗现状[J]. 中国临床药理学与治疗学, 2022, 27(10): 1133-1147.
[11]	郝伟, 左东泽, 张俊秀, 蒋莉莉, 熊莺, 杨解人. 二甲双胍对TGF-β1诱导的大鼠肺泡上皮II型细胞间质转分化的影响[J]. 中国临床药理学与治疗学, 2021, 26(7): 744-752.
[12]	王睿, 潘进进, 李华, 袁予辉. 褪黑素调节肺动脉高压的作用与机制研究进展[J]. 中国临床药理学与治疗学, 2021, 26(4): 444-448.
[13]	胡晓燕, 徐秋萍. 左西孟旦在心脏外科术后重症患者的应用研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1027-1032.
[14]	胡文艳, 李梅, 刘华宝, 饶春燕, 李泓町. 人参皂苷通过Aldolase/AMPK/PINK1信号通路减轻油酸诱导的HL-7702细胞损伤[J]. 中国临床药理学与治疗学, 2020, 25(6): 633-639.
[15]	王超，格根图雅，徐磊. 硼替佐米治疗肺动脉高压的作用机制[J]. 中国临床药理学与治疗学, 2019, 24(8): 957-960.